Enfusion, Inc.
(ENFN)
Add Watchlist
9.67 USD +0.05
Closed: 17 May, 3:55 pm
Symbol ENFN
Market Cap 888.7M
Price 9.67
Open 9.69
52-wk High 11.56
50 Day Avg 9.29
Earnings Announcement 2024-08-06
Website https://www.enfusion.com
Name Enfusion, Inc.
Shares Outstanding 91,911,446
Change % 0.3112%
Low 9.53
52-wk Low 7.52
200 Day Avg 9.06
Last Dividend 0.00
Exchange NYSE
Volume 287,227
Previous Close 9.64
High 9.70
EPS 0.02
PE 483.50
Avg Volume 429,425
CUSIP 292812104
Enfusion, Inc. Outlook
Description Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
Currency USD
ISIN US2928121043
Industry Software - Application
Changes 0.03
CUSIP 292812104
Range 7.52 - 11.56
Beta 0.97
CIK 0001868912

Enfusion, Inc. News

11-May-2024 12:13 PM

Enfusion, Inc. (ENFN) Q1 2024 Earnings Call Transcript

Enfusion, Inc. (NYSE:ENFN ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Bill Wright - Head, Investor Relations Oleg Movchan - Chief Executive Officer Brad Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Jeffrey Lane - Stifel Kevin McVeigh - UBS Alexei Gogolev - JPMorgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Operator Good morning, ladies and gentlemen. Thank you for standing by.

09-May-2024 10:36 AM

Enfusion (ENFN) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Enfusion (ENFN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

19-Apr-2024 12:37 AM

Enfusion Announces Date of First Quarter 2024 Results

NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its first quarter 2024 financial results before the U.S. financial markets open on Thursday, May 9, 2024. Management will host a conference call and webcast that same morning … The post Enfusion Announces Date of First Quarter 2024 Results appeared first on Headlines of Today...

18-Apr-2024 8:30 AM

Enfusion Announces Date of First Quarter 2024 Results

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its first quarter 2024 financial results before the U.S. financial markets open on Thursday, May 9, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ID n.

12-Apr-2024 2:40 PM

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

NEW YORK , April 12, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

04-Apr-2024 7:15 PM

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

NEW YORK , April 4, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

04-Apr-2024 7:00 AM

The 3 Most Undervalued Under-$10 Stocks to Buy in April 2024

Discovering and allocating to undervalued stocks is a key element of successful investing. Stocks are considered “undervalued” when they trade below what people think their intrinsic value is.

02-Apr-2024 7:30 AM

ConnexPay Appoints Ben Peters as Chief Executive Officer

ATLANTA--(BUSINESS WIRE)-- #simplyconnectingpayments--ConnexPay has announced the appointment of Ben Peters as chief executive officer. Peters brings more than two decades of experience.

31-Mar-2024 11:20 AM

Enfusion: TAM Penetration Continues To Progress Well

ENFN reported solid Q4 earnings with accelerating revenue growth and a strong pipeline. The company is successfully penetrating the total addressable market (TAM) in the asset management industry. ENFN's focus on product innovation and total cost of ownership (TCO) advantage will drive future growth and close the valuation gap with peers.

27-Mar-2024 5:25 PM

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. - ENFN

NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

21-Mar-2024 8:00 AM

Kayne Anderson Strengthens Investment Operations After Successful Platform Migration to Enfusion

NEW YORK--(BUSINESS WIRE)--Enfusion, a best-in-class software-as-a-service (SaaS) platform for investment managers, today announced the completion of the second phase of a strategic investment management platform migration by Kayne Anderson. Kayne Anderson is a leading alternative investment management firm focused on real estate, infrastructure, energy, credit, and growth capital. The first phase focused on Order and Execution Management and successfully concluded following a three-month disru.